Literature DB >> 11034370

Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis.

M M Simon1, P Waring, M Lobigs, A Nil, T Tran, R T Hla, S Chin, A Müllbacher.   

Abstract

Cytotoxic T (Tc) cells deficient in perforin lyse Fas-negative targets after lengthy incubation periods. This process is independent of granzymes, and killing occurs via the Fas pathway for the following reasons. Interaction of perforin-deficient Tc cells with Fas-negative targets leads to an up-regulation of Fas that is dependent on Ag recognition, de novo synthesis, and transport of proteins to the target cell surface. Treatment of effectors with brefeldin A, but not with the exocytosis inhibitor concanamycin, inhibited this process. Lysis of targets is inhibited by anti-Fas Abs, soluble mouse Fas-Fc, and the caspase-cascade inhibitor, crm-A. Targets from Fas-mutant lpr mice are refractory to lysis, and Tc cells from mice deficient in Fas- and perforin-mediated lysis do not lyse Fas-negative targets. The possible relevance of this exocytosis-independent cytolytic process in the regulation of T cell activity and control of pathogens is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034370     DOI: 10.4049/jimmunol.165.7.3663

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Creation of killer poxvirus could have been predicted.

Authors:  A Müllbacher; M Lobigs
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.

Authors:  Vijay Panchanathan; Geeta Chaudhri; Gunasegaran Karupiah
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.

Authors:  Wen-Fang Cheng; Chien-Nan Lee; Yi-Ning Su; Ming-Cheng Chang; Wen-Chun Hsiao; Chi-An Chen; Chang-Yao Hsieh
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

4.  Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection.

Authors:  S Balkow; A Kersten; T T Tran; T Stehle; P Grosse; C Museteanu; O Utermöhlen; H Pircher; F von Weizsäcker; R Wallich; A Müllbacher; M M Simon
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Perforin and Fas act together in the induction of apoptosis, and both are critical in the clearance of lymphocytic choriomeningitis virus infection.

Authors:  Miriam Rode; Sandra Balkow; Vera Sobek; Reina Brehm; Praxedis Martin; Astrid Kersten; Tilman Dumrese; Thomas Stehle; Arno Müllbacher; Reinhard Wallich; Markus M Simon
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma.

Authors:  Arno Sungarian; Deus Cielo; Prakash Sampath; Nathaniel Bowling; Peter Moskal; Jack R Wands; Suzanne M de la Monte
Journal:  J Oncol       Date:  2010-01-11       Impact factor: 4.375

7.  Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.

Authors:  German G Gomez; Carol A Kruse
Journal:  J Immunother       Date:  2007-04       Impact factor: 4.456

8.  Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  Sarah Nikiforow; Kim Bottomly; George Miller; Christian Münz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Up-regulation of Fas (CD95) expression in tumour cells in vivo.

Authors:  Naama Peshes-Yaloz; Dalia Rosen; Paul M Sondel; Peter H Krammer; Gideon Berke
Journal:  Immunology       Date:  2007-04       Impact factor: 7.397

10.  Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb.

Authors:  Julián Pardo; Ignacio Melero; Aizea Morales-Kastresana; Elena Catalán; Sandra Hervás-Stubbs; Asis Palazón; Arantza Azpilikueta; Elixabet Bolaños; Alberto Anel
Journal:  J Immunother Cancer       Date:  2013-05-29       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.